Thermo Fisher Scientific Durvalumab Monoclonal Antibody (4B5)

Applications

ELISA (ELISA)

• Tested Dilution: 0.01–0.1 µg/mL

Product Specifications

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Durvalumab (trade name Imfinzi) is an FDA-approved anti-cancer drug developed by Medimmune/AstraZeneca. It is a human IgG1 kappa monoclonal antibody functioning as a checkpoint inhibitor that blocks the interaction between programmed cell death ligand 1 (PD-L1) and PD-1 (CD279).

Anti-Durvalumab Antibody (4B5), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.

Target Information

Durvalumab (Imfinzi) is a human IgG1 kappa monoclonal antibody developed by Medimmune/AstraZeneca. It acts as a checkpoint inhibitor by blocking the PD-L1 and PD-1 (CD279) interaction.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.